Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Cognito Therapeutics is raising $126,175,917.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brent Vaughan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimers disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimers disease and expects to start pivotal studies in 2022. The companys technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

To learn more about Cognito Therapeutics, visit http://www.cognitotx.com/

Contact:
Brent Vaughan, Chief Executive Officer
857-201-5088
https://www.linkedin.com/in/brent-vaughan-753738/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved